Immunoscore®, which evaluates the abundance of the CD3+ and CD8+ cells, was validated as an independent prognostic factor in colon cancer stage I–III6,7 and surpassed established clinical parameters such as T and N stage. Here, CD8A is linked to malignant colon neoplasm.